Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance

Crispr Therapeutics AGTrade
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETFTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Crispr Therapeutics AG trades at $53.86 (market cap $5.23B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.75. Which is the better fit depends on your goals.

CRSPQDTY
Market Cap
$5.23B
Sector
HealthIncome / Options Overlay
52-Week High
$76.78$46.71
52-Week Low
$44.34$36.57
Enterprise Value
$3.65B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.

The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.

YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF

QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.

Read more on QDTY